ClinicalTrials.gg
CompletedNCT05062330Updated Mar 18, 2025Results posted

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
3rd of 11
361 · median 158
Started
2021
with 3 others
Phase 3
5 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 6th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age (either gender and any race);
  • Reported history of dry eye for at least 6 months prior to Visit 1;
  • Reported history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1

Exclusion criteria

Exclusion Criteria:

  • slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial;
  • Eye drop use within 2 hours of Visit 1;
  • Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days of Visit 1;
  • Be receiving systemic therapy (not including inhaled corticosteroids) within 14 days of Visit 1 or anticipate such therapy throughout the study period;
  • Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
  • Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Placebo comparator
    Vehicle Ophthalmic Solution administered 7 times over two consecutive days

    Drug: Vehicle Ophthalmic Solution

Interventions

  • Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days

  • DrugVehicle Ophthalmic Solution

    Vehicle Ophthalmic Solution administered 7 times over two consecutive days

06

What researchers measure

Primary outcomes

  1. Schirmer Test Mean Change From Baseline

    Change from baseline comparison of reproxalap to vehicle for Schirmer test (0 to 35 mm). Higher scores represent greater tear production. The least squares mean (standard error) was derived from a mixed model repeated measures analysis of change from baseline, with baseline as a covariate, and time point and treatment group as factors.

    Time frame: The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.

  2. Number of Subject Eyes That Are Schirmer Test Responders

    Comparison of reproxalap to vehicle for number of subject eyes that are Schirmer test responders (10 millimeters or more increase from baseline). A generalized estimating equation analysis was performed with baseline as a covariate, and time point and treatment group as factors.

    Time frame: The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.

07

Results

Posted Mar 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneReproxalapVehicle
Started181180
Completed168168
Not completed1312

Outcome measures

PrimarySchirmer Test Mean Change From Baseline

Change from baseline comparison of reproxalap to vehicle for Schirmer test (0 to 35 mm). Higher scores represent greater tear production. The least squares mean (standard error) was derived from a mixed model repeated measures analysis of change from baseline, with baseline as a covariate, and time point and treatment group as factors.

Time frame:
The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.
Reported as:
Least squares mean · length in millimeters
Schirmer Test Mean Change From Baseline
length in millimetersReproxalapVehicle
Schirmer Test Mean Change From Baseline1.8 ± 0.4-0.5 ± 0.4
PrimaryNumber of Subject Eyes That Are Schirmer Test Responders

Comparison of reproxalap to vehicle for number of subject eyes that are Schirmer test responders (10 millimeters or more increase from baseline). A generalized estimating equation analysis was performed with baseline as a covariate, and time point and treatment group as factors.

Time frame:
The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.
Reported as:
Number · eyes
Number of Subject Eyes That Are Schirmer Test Responders
eyesReproxalapVehicle
Number of Subject Eyes That Are Schirmer Test Responders11654
Statistical analysis
  • Reproxalap vs Vehicle · Generalized estimating equation · p = <0.0001 · Odds ratio (or): 2.63 · 95% CI 1.67 to 4.13

Adverse events

Collected over The safety assessment period was two days.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap0/181 (0%)0/181 (0%)145/181 (80.1%)
Vehicle0/180 (0%)0/180 (0%)6/180 (3.3%)
Most frequent other events
Most frequent other events
EventReproxalapVehicle
General disorders and administration site conditionsGeneral disorders145/1816/180

Baseline characteristics

Intent-to-treat population

Age, Categorical
Age, Categorical(Participants)ReproxalapVehicleTotal
<=18 years000
Between 18 and 65 years8398181
>=65 years9882180
Age, Continuous
Age, Continuous(years)ReproxalapVehicleTotal
Mean64.2 ± 12.261.9 ± 12.963.1 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)ReproxalapVehicleTotal
Female123126249
Male5854112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ReproxalapVehicleTotal
Hispanic or Latino10313
Not Hispanic or Latino171177348
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ReproxalapVehicleTotal
American Indian or Alaska Native000
Asian91019
Native Hawaiian or Other Pacific Islander000
Black or African American253661
White147132279
More than one race022
Unknown or Not Reported000
08

Study locations

1 site
  • Andover Eye Associates (Raynham)
    Raynham, Massachusetts 02767, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2022, 6 months.

Results were first posted in Mar 2025, 3 years after primary completion. A results delay was requested in Feb 2023.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 30, 2021
StartActual
Aug 28, 2021
Primary completionActual
Mar 4, 2022
CompletionActual
Mar 4, 2022
Results delay requested
Feb 10, 2023
Results first posted
Mar 18, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05062330
Responsible party
Sponsor
First posted
Sep 30, 2021
Start date
Aug 28, 2021
Primary completion
Mar 4, 2022
Completion
Mar 4, 2022
Results posted
Mar 18, 2025
Last update
Mar 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion